Background Easily distributed oral antivirals are urgently needed to treat coronavirus
disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of …

There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …

Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

Background Throughout the time of the global pandemic of SARS-CoV-2 virus, there has
been a compelling necessity for the development of effective antiviral agents and …

Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Background The effects of molnupiravir in treating patients with non-severe COVID-19
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …

Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …